Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biolinerx Ltd (BLRX)

Biolinerx Ltd (BLRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,803
  • Shares Outstanding, K 19,873
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,450 K
  • 60-Month Beta 2.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.40
Trade BLRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.47
  • Number of Estimates 1
  • High Estimate -0.47
  • Low Estimate -0.47
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -17.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +0.63%
on 10/26/20
1.7000 -11.21%
on 09/30/20
-0.0506 (-3.24%)
since 09/25/20
3-Month
1.5000 +0.63%
on 10/26/20
2.5700 -41.27%
on 08/05/20
-0.5406 (-26.37%)
since 07/24/20
52-Week
1.0609 +42.28%
on 03/18/20
3.0400 -50.35%
on 11/05/19
-1.1606 (-43.47%)
since 10/25/19

Most Recent Stories

More News
Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up

Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.

IRWD : 9.57 (-0.73%)
BLRX : 1.5100 (-2.58%)
ALDX : 7.30 (-4.45%)
HRTX : 16.38 (-0.73%)
Radius Completes Enrollment in Phase III Osteoporosis Study

Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

BPTH : 4.11 (-12.74%)
BLRX : 1.5100 (-2.58%)
RDUS : 13.81 (+0.22%)
CTLT : 91.07 (-3.14%)
Savara to Stop Study on Molgradex for NTM Lung Infection

Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.

JAZZ : 149.18 (-0.72%)
BLRX : 1.5100 (-2.58%)
ALDX : 7.30 (-4.45%)
SVRA : 1.1700 (-0.85%)
Onconova's Cancer Study Fails to Meet Endpoint, Shares Down

Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.

BPTH : 4.11 (-12.74%)
BLRX : 1.5100 (-2.58%)
PCRX : 53.79 (-3.03%)
ONTX : 0.2651 (-5.32%)
BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis

, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that a sufficient number of patients (~65% of the original...

BLRX : 1.5100 (-2.58%)
Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

BLRX : 1.5100 (-2.58%)
PCRX : 53.79 (-3.03%)
ESALY : 79.9600 (+0.39%)
ATXI : 3.25 (-6.07%)
Catalyst's (CPRX) Q2 Earnings & Revenues Beat Estimates

Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.

BLRX : 1.5100 (-2.58%)
ACRX : 1.7100 (-2.84%)
BSTC : 88.17 (+0.01%)
CPRX : 3.09 (-3.13%)
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line

Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.

BLRX : 1.5100 (-2.58%)
PCRX : 53.79 (-3.03%)
BLCM : 6.37 (+2.74%)
ATNM : 11.40 (+1.06%)
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update

, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended and provides...

BLRX : 1.5100 (-2.58%)
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

MRK : 78.80 (-1.29%)
BMY : 59.45 (-1.13%)
BLRX : 1.5100 (-2.58%)
CORT : 17.78 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040,...

See More

Key Turning Points

2nd Resistance Point 1.5764
1st Resistance Point 1.5632
Last Price 1.5100
1st Support Level 1.5384
2nd Support Level 1.5268

See More

52-Week High 3.0400
Fibonacci 61.8% 2.2840
Fibonacci 50% 2.0504
Fibonacci 38.2% 1.8169
Last Price 1.5100
52-Week Low 1.0609

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar